Syngene is using virtual audits to enable clients/regulators experience its capability and infrastructure, without physically visiting the site.

One of the largest Stability facilities in Asia, Syngene supports both small and large molecules from early development to CMC 

Syngene has considerable experience solving synthetic chemistry and purification challenges with PROTACS.

Syngene offers Biologics development and Biomanufacturing solutions in both mammalian and microbial systems.

Syngene  has full value-chain Process Research and Development (PRD) capabilities for NCEs and advanced intermediates.

Syngene supports early-phase to late-phase clinical trials required for drug development programs across a wide range of therapeutic areas.

Syngene supports manufacturing of regulatory starting materials, APIs, HPAPI, NCEs and novel advanced intermediates

Syngene supports both development  and manufacturing of Drug Products from early to late stage.

Syngene’s services encompass Therapeutic oligonucleotides,  Diagnostic Oligonucleotides, Enzymatic synthesis and  analytical services.